EydisBio

EydisBio is a biotech startup based in Durham, NC, specializing in the development of highly selective small molecule kinase inhibitors targeting autoimmune and inflammatory diseases. Their primary focus is on creating a novel TAK1 inhibitor that is orally bioavailable, aimed at providing safer and more effective treatments for conditions such as r... heumatoid arthritis, chronic pain, and systemic sclerosis. The company addresses significant unmet medical needs, particularly for patients seeking alternatives to existing anti-TNF biologics. EydisBio's innovative approach leverages a unique discovery platform to develop a pipeline of small molecules that target disease-driving proteins.Read More